Literature DB >> 2199349

Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy.

K Tarao1, T Ikeda, K Hayashi, A Sakurai, T Okada, T Ito, H Karube, T Nomoto, T Mizuno, K Shindo.   

Abstract

Vancomycin hydrochloride (2 g daily) was administered to 12 patients with cirrhosis and lactulose resistant portal systemic encephalopathy in a double blind crossover trial. All 12 patients showed a remarkable clinical improvement after vancomycin treatment. The mean (SE) electroencephalographic (EEG) frequency changed from 6.3 (0.2) to 8.5 (0.2) cps (p less than 0.001) and the mean arterial ammonia concentration from 152 (4) micrograms/ml to 97 (8) micrograms/ml (p less than 0.001). Their clinical condition deteriorated when treatment was switched to lactulose, returning to the previous slower EEG frequency and high arterial ammonia concentrations. Vancomycin seems to be effective in chronic portal systemic encephalopathy in patients who are not helped by lactulose alone.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2199349      PMCID: PMC1378501          DOI: 10.1136/gut.31.6.702

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  The electroencephalograph in liver disease.

Authors:  B G PARSONS-SMITH; W H SUMMERSKILL; A M DAWSON; S SHERLOCK
Journal:  Lancet       Date:  1957-11-02       Impact factor: 79.321

2.  Morphological effects of high dose neomycin sulphate on the small and large intestine.

Authors:  P A Van Leeuwen; J Drukker; N M Van der Kleyn; A E Van den Boogaard; P B Soeters
Journal:  Acta Morphol Neerl Scand       Date:  1986

3.  The importance of the small intestine in gut ammonium production in the fasting dog.

Authors:  F L Weber; G L Veach
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

4.  Bacterial ureases in uraemic men.

Authors:  C L Brown; M J Hill; P Richards
Journal:  Lancet       Date:  1971-08-21       Impact factor: 79.321

5.  [Clinical significance of anaerobic gram-negative bacteria in hepatic encephalopathy and the therapeutic effects of vancomycin hydrochloride on hepatic encephalopathy].

Authors:  K Tarao; T Ikeda; K Hayashi; A Sakurai
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1985-08

6.  [Direct colorimetry of ammonia in the blood].

Authors:  H Okuda; S Fujii
Journal:  Saishin Igaku       Date:  1966-03

7.  Nitrogen in fecal bacterial, fiber, and soluble fractions of patients with cirrhosis: effects of lactulose and lactulose plus neomycin.

Authors:  F L Weber; J G Banwell; K M Fresard; J H Cummings
Journal:  J Lab Clin Med       Date:  1987-09

8.  The effect of normalization of plasma amino acids on hepatic encephalopathy in man.

Authors:  J E Fischer; H M Rosen; A M Ebeid; J H James; J M Keane; P B Soeters
Journal:  Surgery       Date:  1976-07       Impact factor: 3.982

9.  The role of plasma amino acids in hepatic encephalopathy.

Authors:  J E Fischer; J M Funovics; A Aguirre; J H James; J M Keane; R I Wesdorp; N Yoshimura; T Westman
Journal:  Surgery       Date:  1975-09       Impact factor: 3.982

10.  Treatment of hepatic encephalopathy with metronidazole.

Authors:  M H Morgan; A E Read; D C Speller
Journal:  Gut       Date:  1982-01       Impact factor: 23.059

View more
  18 in total

Review 1.  Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management.

Authors:  T Gerber; H Schomerus
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 2.  The extrahepatic consequences of cirrhosis.

Authors:  Jin Kee Ho; Eric Yoshida
Journal:  MedGenMed       Date:  2006-03-02

Review 3.  Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L-ornithine-L-aspartate in the management of HE.

Authors:  Gerald Kircheis
Journal:  Metab Brain Dis       Date:  2016-11-12       Impact factor: 3.584

Review 4.  Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.

Authors:  Karim M Eltawil; Marie Laryea; Kevork Peltekian; Michele Molinari
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

Review 5.  Pathophysiology, diagnosis, and management of hepatic encephalopathy.

Authors:  Christopher Sheasgreen; Lucy Lu; Ameen Patel
Journal:  Inflammopharmacology       Date:  2014-10-10       Impact factor: 4.473

Review 6.  Management of hepatic encephalopathy in the hospital.

Authors:  Michael D Leise; John J Poterucha; Patrick S Kamath; W Ray Kim
Journal:  Mayo Clin Proc       Date:  2014-01-08       Impact factor: 7.616

7.  Hepatic Encephalopathy.

Authors:  Srinivasan Dasarathy; Kevin D. Mullen
Journal:  Curr Treat Options Gastroenterol       Date:  2001-12

8.  Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study.

Authors:  Claudia Sama; Antonio Maria Morselli-Labate; Paolo Pianta; Laura Lambertini; Sonia Berardi; Gabriella Martini
Journal:  Curr Ther Res Clin Exp       Date:  2004-09

Review 9.  Antibiotics for the treatment of hepatic encephalopathy.

Authors:  Kavish R Patidar; Jasmohan S Bajaj
Journal:  Metab Brain Dis       Date:  2013-02-08       Impact factor: 3.584

Review 10.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.